NVCR Latest Headlines

H.C. Wainwright Keeps Their Buy Rating on NovoCure (NVCR)

at www.tipranks.com (Mon, 20-Apr 1:45 PM)

Novocure’s TTFields Therapy Achieves 74.4% Disease Control Rate in Metastatic Pancreatic Cancer—Phase 2 PANOVA-4 Results Impress

Market Chameleon (Thu, 26-Mar 9:19 AM)

Novocure Hits Revenue Milestones as FDA Approval of Optune Pax Expands Oncology Pipeline

Market Chameleon (Thu, 26-Feb 8:07 AM)

British Columbia Becomes First Canadian Province to Cover Novocure’s TTFields Therapy for Newly Diagnosed Glioblastoma

Market Chameleon (Wed, 25-Feb 11:59 AM)

FDA Approval of Optune Pax Marks Breakthrough for Pancreatic Cancer Treatment—Key Survival Gains Reported in PANOVA-3 Trial

Market Chameleon (Thu, 12-Feb 10:31 AM)